bevacizumab

Trastuzumab deruxtecan is a HER2-directed ADC that pioneered therapy for HER2-low breast cancer. The DESTINY program has reshaped global guidelines, with massive cross-tumor potential across breast, gastric, and lung cancers, setting the ADC technology benchmark.

Vedolizumab is an anti-α4β7 integrin mAb for ulcerative colitis and Crohn's disease. Its gut-selective anti-lymphocyte trafficking mechanism avoids systemic immunosuppression and PML risk, making it the preferred safety option among IBD biologics.

Abaloparatide is a PTHrP(1-34) analog acting as an agonist at the PTH1 receptor (PTH1R). It activates the cAMP signaling pathway to stimulate osteoblastic activity and new bone formation. Administered as 80 mcg subcutaneously once daily. Abaloparatide demonstrates rapid and robust bone formation with the b...

Amphotericin B is a true single bilayer liposomal drug delivery system with amphotericin B intercalated within a liposomal membrane composed of hydrogenated soy phosphatidylcholine, distearoyl phosphatidylglycerol, and cholesterol. Liposomes are less than 100 nm in diameter. The liposomal encapsulation per...

Aprepitant, a highly selective neurokinin-1 receptor antagonist, provides superior protection against both acute and delayed chemotherapy-induced nausea and vomiting compared to conventional antiemetic agents, with a single dose offering sustained efficacy over many hours. Its ability to be combined with 5...

Atezolizumab is an anti-PD-L1 mAb and the first approved for NSCLC first-line immunotherapy combinations. With differentiated positioning in urothelial carcinoma and HCC (combined with bevacizumab), it remains a significant competitor in the PD-L1 landscape.

Bupivacaine utilizes proprietary DepoFoam technology to encapsulate bupivacaine within multivesicular liposomes, enabling sustained analgesia for up to 72 hours through a unique tri-phasic release mechanism involving initial burst, membrane diffusion, and particle erosion. This prolonged duration of action...

Daratumumab is an anti-CD38 mAb for multiple myeloma across all lines of therapy. From first-line to relapsed settings, its subcutaneous Faspro formulation compresses infusion from hours to minutes, making it the absolute cornerstone of MM treatment.

Denosumab is a human anti-RANKL mAb; Prolia for osteoporosis and Xgeva for bone metastases. Its semiannual subcutaneous dosing offers superior compliance vs oral bisphosphonates, with dual-market positioning across orthopedics and oncology.

Ipratropium Bromide and Salbutamol is a combination of ipratropium bromide (anticholinergic) and albuterol sulfate (beta2-adrenergic agonist) delivered via the soft mist inhaler. It provides superior relief of bronchospasm compared to either agent alone in COPD patients with persistent symptoms despite reg...

Leuprorelin uses lyophilized microsphere technology with leuprolide acetate embedded in biodegradable PLGA polymer microcapsules. The active drug is released in two phases—diffusion and bioerosion—enabling 3-month or 6-month dosing intervals. As a GnRH agonist, it induces pituitary desensitization to reduc...

Nusinersen is a modified antisense oligonucleotide (ASO) administered intrathecally. It binds to the ISS-N1 sequence in intron 7 of SMN2 pre-mRNA, promoting exon 7 inclusion and production of full-length functional SMN protein. Approved across all SMA phenotypes including Type I, II, III, and presymptomati...